For patients with metastatic triple negative breast cancer on nab-paclitaxel + atezolizumab who have an ongoing response, are you continuing immunotherapy after the FDA withdrawal of atezolizumab?  

Yes, I would consider continuing immunotherapy. We know that the full benefit of immune checkpoint inhibitors may be delayed and may be durable as opposed to single agent chemotherapy. Even in patients with an early response to atezo and nab-paclitaxel, I would continue the combination if possible, ...